Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026

HILLSIDE, NJ / ACCESS Newswire / September 25, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2026. Revenue for the quarter ended June 30, 2026 was $9.8 million compared to $14.2 million for the quarter ended June 30, 2025, a decrease of $4.4 million or 31.0%. The Company had an operating loss of $0.9 million compared to operating income of approximately $0.6 million in the quarters ended June 30, 2026 and 2025, respectively.

Revenues for the fiscal year ended June 30, 2026 were $43.9 million compared to $54.4 million for the fiscal year ended June 30, 2025, a decrease of $10.5 million or 19.3%. The Company had an operating loss for the fiscal year ended June 30, 2026 of approximately $2.7 million compared to operating income of $2.0 million for the fiscal year ended June 30, 2025.